An experimental rat model of sporadic Alzheimer’s disease and rescue of cognitive impairment with a neurotrophic peptide

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Acta Neuropathologica

• Publication date

  Unknown publication date

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1007/s00401-011-0908-xPMID 22083255PMCID PMC3889170
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Conditional reduction of adult neurogenesis impairs bidirectional hippocampal synaptic plasticity

  2011cited by this paper
• Synaptic Degeneration in Alzheimer's Disease

  2011cited by this paper
• Opportunities and challenges in developing Alzheimer disease therapeutics

  2011cited by this paper
• Phosphoprotein phosphatase 2A: a novel druggable target for Alzheimer's disease.

  2011cited by this paper
• Intraneuronal APP, Not Free Aβ Peptides in 3xTg-AD Mice: Implications for Tau versus Aβ-Mediated Alzheimer Neurodegeneration

  2011cited by this paper
• Enhancement of dentate gyrus neurogenesis, dendritic and synaptic plasticity and memory by a neurotrophic peptide.

  2011cited by this paper
• Anti-aβ therapeutics in Alzheimer's disease: the need for a paradigm shift.

  2011cited by this paper
• New neurons and new memories: how does adult hippocampal neurogenesis affect learning and memory?

  2010influential reference
• Is tau a suitable therapeutical target in tauopathies?

  2010cited by this paper
• Pharmacologic reversal of neurogenic and neuroplastic abnormalities and cognitive impairments without affecting Aβ and tau pathologies in 3xTg-AD mice

  2010cited by this paper
• Beneficial Effect of a CNTF Tetrapeptide on Adult Hippocampal Neurogenesis, Neuronal Plasticity, and Spatial Memory in Mice

  2010cited by this paper
• The carboxy‐terminal fragment of inhibitor‐2 of protein phosphatase‐2A induces Alzheimer disease pathology and cognitive impairment

  2010cited by this paper
• Ciliary Neurotrophic Factor Cell-Based Delivery Prevents Synaptic Impairment and Improves Memory in Mouse Models of Alzheimer's Disease

  2010cited by this paper
• Synaptic degeneration in Alzheimer’s disease

  2009cited by this paper
• Protein phosphatase 2A in Alzheimer's disease.

  2009cited by this paper
• Site-specific integration of adeno-associated virus involves partial duplication of the target locus

  2009cited by this paper
• TrkB Modulates Fear Learning and Amygdalar Synaptic Plasticity by Specific Docking Sites

  2009cited by this paper
• The Amyloid Hypothesis of Alzheimer ’ s Disease : Progress and Problems on the Road to Therapeutics

  2009cited by this paper
• Protein Synthesis and Neurotrophin-Dependent Structural Plasticity of Single Dendritic Spines

  2008cited by this paper
• Ciliary Neurotrophic Factor Mediates Dopamine D2 Receptor-Induced CNS Neurogenesis in Adult Mice

  2008cited by this paper
• Mechanisms and functional implications of adult neurogenesis.

  2008cited by this paper
• Failure of Neuronal Maturation in Alzheimer Disease Dentate Gyrus

  2008cited by this paper
• Kinases and phosphatases and tau sites involved in Alzheimer neurofibrillary degeneration

  2007cited by this paper
• A critical period for enhanced synaptic plasticity in newly generated neurons of the adult brain.

  2007influential reference
• Alzheimer neurofibrillary degeneration: significance, etiopathogenesis, therapeutics and prevention

  2007cited by this paper
• Novel rat Alzheimer's disease models based on AAV-mediated gene transfer to selectively increase hippocampal Aβ levels

  2007cited by this paper
• Preferential incorporation of adult-generated granule cells into spatial memory networks in the dentate gyrus

  2007cited by this paper
• Beyond amyloid: the next generation of Alzheimer's disease therapeutics.

  2007cited by this paper
• Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model.

  2007cited by this paper
• Adult neurogenesis and neurodegenerative disease.

  2006cited by this paper
• Reduction of Soluble Aβ and Tau, but Not Soluble Aβ Alone, Ameliorates Cognitive Decline in Transgenic Mice with Plaques and Tangles*

  2006cited by this paper
• Truncated tau from sporadic Alzheimer's disease suffices to drive neurofibrillary degeneration in vivo

  2006cited by this paper
• Brain-Derived Neurotrophic Factor and Antidepressant Drugs Have Different But Coordinated Effects on Neuronal Turnover, Proliferation, and Survival in the Adult Dentate Gyrus

  2005cited by this paper
• Contributions of protein phosphatases PP1, PP2A, PP2B and PP5 to the regulation of tau phosphorylation

  2005cited by this paper
• Up-regulation of inhibitors of protein phosphatase-2A in Alzheimer's disease.

  2005cited by this paper
• Inhibitors of protein phosphatase‐2A from human brain structures, immunocytological localization and activities towards dephosphorylation of the Alzheimer type hyperphosphorylated tau

  2005cited by this paper
• SET protein (TAF1β, I2PP2A) is involved in neuronal apoptosis induced by an amyloid precursor protein cytoplasmic subdomain

  2005cited by this paper
• Primitive neural stem cells from the mammalian epiblast differentiate to definitive neural stem cells under the control of Notch signaling.

  2004cited by this paper
• Altered Expression Levels of the Protein Phosphatase 2A ABαC Enzyme Are Associated with Alzheimer Disease Pathology

  2004cited by this paper
• LTP and LTD: an embarrassment of riches.

  2004cited by this paper
• Trk receptors: roles in neuronal signal transduction.

  2003cited by this paper
• Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction.

  2003cited by this paper
• BDNF and activity-dependent synaptic modulation.

  2003cited by this paper
• The dentate gyrus neurogenesis: a therapeutic target for Alzheimer's disease

  2003cited by this paper
• The neuroprotective effects of Cerebrolysin™ in a transgenic model of Alzheimer’s disease are associated with improved behavioral performance

  2003cited by this paper
• From acquisition to consolidation: on the role of brain-derived neurotrophic factor signaling in hippocampal-dependent learning.

  2002cited by this paper
• Alzheimer's Disease Is a Synaptic Failure

  2002cited by this paper
• The Amyloid Hypothesis of Alzheimer's Disease: Progress and Problems on the Road to Therapeutics

  2002cited by this paper
• Localized synaptic potentiation by BDNF requires local protein synthesis in the developing axon.

  2002cited by this paper
• Production and purification of serotype 1, 2, and 5 recombinant adeno-associated viral vectors.

  2002cited by this paper
• The Protein SET Binds the Neuronal Cdk5 Activator p35 nck5a and Modulates Cdk5/p35 nck5a Activity*

  2002cited by this paper
• Role for brain-derived neurotrophic factor in learning and memory.

  2002cited by this paper
• Regulation of histone acetylation and transcription by INHAT, a human cellular complex containing the set oncoprotein.

  2001cited by this paper
• PP2A mRNA expression is quantitatively decreased in Alzheimer's disease hippocampus.

  2001cited by this paper
• Region-specific neurotrophin imbalances in Alzheimer disease: decreased levels of brain-derived neurotrophic factor and increased levels of nerve growth factor in hippocampus and cortical areas.

  2000cited by this paper
• Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline.

  2000cited by this paper
• Phosphorylation of Microtubule-associated Protein Tau Is Regulated by Protein Phosphatase 2A in Mammalian Brain

  2000cited by this paper
• The Role of Brain-Derived Neurotrophic Factor Receptors in the Mature Hippocampus: Modulation of Long-Term Potentiation through a Presynaptic Mechanism involving TrkB

  2000influential reference
• Modulation of APP processing and secretion by okadaic acid in primary guinea pig neurons

  2000cited by this paper
• Essential role for TrkB receptors in hippocampus-mediated learning.

  1999influential reference
• The regulation of phosphorylation of τ in SY5Y neuroblastoma cells: the role of protein phosphatases

  1998cited by this paper
• Loss of the Presynaptic Vesicle Protein Synaptophysin in Hippocampus Correlates with Cognitive Decline in Alzheimer Disease

  1997cited by this paper
• Purification and characterization of two potent heat-stable protein inhibitors of protein phosphatase 2A from bovine kidney.

  1995cited by this paper
• Hippocampal long-term potentiation is impaired in mice lacking brain-derived neurotrophic factor.

  1995influential reference
• Characterization of Two Distinct Monoclonal Antibodies to Paired Helical Filaments: Further Evidence for Fetal‐Type Phosphorylation of the τ in Paired Helical Filaments

  1993cited by this paper
• Phosphoprotein Phosphatase Activities in Alzheimer Disease Brain

  1993cited by this paper
• Microtubule-associated protein tau. Abnormal phosphorylation of a non-paired helical filament pool in Alzheimer disease.

  1993cited by this paper
• An Embarrassment of Riches

  1992cited by this paper
• Physical basis of cognitive alterations in alzheimer's disease: Synapse loss is the major correlate of cognitive impairment

  1991cited by this paper
• BDNF mRNA is decreased in the hippocampus of individuals with Alzheimer's disease.

  1991cited by this paper
• Unbiased stereological estimation of the total number of neurons in the subdivisions of the rat hippocampus using the optical fractionator

  1991cited by this paper
• A preparation of Alzheimer paired helical filaments that displays distinct tau proteins by polyacrylamide gel electrophoresis.

  1990cited by this paper
• Microtubule-associated polypeptides tau are altered in Alzheimer paired helical filaments.

  1988cited by this paper
• Alzheimerʼs disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein

  1988cited by this paper
• Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology.

  1986cited by this paper
• Place navigation impaired in rats with hippocampal lesions

  1982cited by this paper
• Assay of proteins in the presence of interfering materials.

  1976cited by this paper

• Astrocytes distress triggers brain pathology through induction of δ secretase in a murine model of Alzheimer’s disease

  2025cites this paper
• The effect of tanshinones on cognitive impairments in animal models of Alzheimer’s disease: a systematic review and meta-analysis

  2025cites this paper
• Natural products against tau hyperphosphorylation‐induced aggregates: Potential therapies for Alzheimer's disease

  2025cites this paper
• Potential role of long noncoding RNA maternally expressed gene 3 (MEG3) in the process of neurodegeneration.

  2024cites this paper
• Ellagic acid(EA) ameliorates Alzheimer's disease by reducing Aβ levels, oxidative stress and attenuating inflammation.

  2024cites this paper
• C/EBPβ: A transcription factor associated with the irreversible progression of Alzheimer's disease

  2024cites this paper
• Hyperphosphorylated tau targeting human serum albumin Fusion protein as therapeutics for Alzheimer’s diseases

  2024cites this paper
• Alzheimer’s Disease: Challenges and a Therapeutic Opportunity to Treat It with a Neurotrophic Compound

  2022cites this paper
• The role of protein phosphatase 2A tau axis in traumatic brain injury therapy

  2022cites this paper
• The E3 Ligase TRIM4 Facilitates SET Ubiquitin‐Mediated Degradation to Enhance ER‐α Action in Breast Cancer

  2022cites this paper
• Potential Role of Adult Hippocampal Neurogenesis in Traumatic Brain Injury.

  2021cites this paper
• Leucine Carboxyl Methyltransferase 1 Overexpression Protects Against Cognitive and Electrophysiological Impairments in Tg2576 APP Transgenic Mice

  2021cites this paper
• Pharmacological activities of ginsenoside Rg5 (Review)

  2021cites this paper
• Neurotrophic Treatment Initiated During Early Postnatal Development Prevents the Alzheimer-Like Behavior and Synaptic Dysfunction

  2021cites this paper
• The Complexity of Secondary Cascade Consequent to Traumatic Brain Injury: Pathobiology and Potential Treatments

  2021cites this paper
• Age-Related Transcriptional Deregulation of Genes Coding Synaptic Proteins in Alzheimer's Disease Murine Model: Potential Neuroprotective Effect of Fingolimod

  2021cites this paper
• β-Asarone Attenuates Aβ-Induced Neuronal Damage in PC12 Cells Overexpressing APPswe by Restoring Autophagic Flux

  2021cites this paper
• Reduced Expression of the PP2A Methylesterase, PME-1, or the PP2A Methyltransferase, LCMT-1, Alters Sensitivity to Beta-Amyloid-Induced Cognitive and Electrophysiological Impairments in Mice

  2020influential citation
• δ-secretase in neurodegenerative diseases: mechanisms, regulators and therapeutic opportunities

  2020cites this paper
• Adult Neurogenesis: Facts and Potential Targets in Some Neurological and Neurodegenerative Diseases

  2020cites this paper
• Prenatal to early postnatal neurotrophic treatment prevents Alzheimer-like behavior and pathology in mice

  2020cites this paper
• Born to Protect: Leveraging BDNF Against Cognitive Deficit in Alzheimer’s Disease

  2020cites this paper
• Why delay in effective treatment for Alzheimer's disease and related conditions.

  2019cites this paper
• Neuroprotective Effects of Ginseng Phytochemicals: Recent Perspectives

  2019cites this paper
• Ten Years of Tau-Targeted Immunotherapy: The Path Walked and the Roads Ahead

  2018cites this paper
• Rac1 activation links tau hyperphosphorylation and Aβ dysmetabolism in Alzheimer’s disease

  2018cites this paper
• Mini-GAGR, an intranasally applied polysaccharide, activates the neuronal Nrf2-mediated antioxidant defense system

  2018cites this paper
• A Novel Therapeutic Approach to Treat Alzheimer’s Disease by Neurotrophic Support During the Period of Synaptic Compensation

  2018cites this paper
• Early neurotrophic pharmacotherapy rescues developmental delay and Alzheimer’s-like memory deficits in the Ts65Dn mouse model of Down syndrome

  2017cites this paper
• Oncogenic Role of SET/I2PP2A for Gynecologic Cancers.

  2017cites this paper
• TFP5, a Peptide Inhibitor of Aberrant and Hyperactive Cdk5/p25, Attenuates Pathological Phenotypes and Restores Synaptic Function in CK-p25Tg Mice

  2017cites this paper
• Pathologic significance of SET/I2PP2A-mediated PP2A and non-PP2A pathways in polycystic ovary syndrome (PCOS).

  2017cites this paper
• Neural Regeneration as a Disease-Modifying Therapeutic Strategy for Alzheimer’s Disease

  2017cites this paper
• Prevention of dendritic and synaptic deficits and cognitive impairment with a neurotrophic compound

  2017cites this paper
• Eicosanoyl-5-hydroxytryptamide (EHT) prevents Alzheimer’s disease-related cognitive and electrophysiological impairments in mice exposed to elevated concentrations of oligomeric beta-amyloid

  2017cites this paper
• Defeating Alzheimer's disease and other dementias: a priority for European science and society.

  2016cites this paper
• Neurotrophic factor small-molecule mimetics mediated neuroregeneration and synaptic repair: emerging therapeutic modality for Alzheimer’s disease

  2016cites this paper
• BBB-Permeable, Neuroprotective, and Neurotrophic Polysaccharide, Midi-GAGR

  2016cites this paper
• Tau and neurodegenerative disease: the story so far

  2016cites this paper
• (-)-SCR1693 Protects against Memory Impairment and Hippocampal Damage in a Chronic Cerebral Hypoperfusion Rat Model

  2016cites this paper
• Gene Therapy for Neurological Disorders

  2016cites this paper
• Sodium selenate, a protein phosphatase 2A activator, mitigates hyperphosphorylated tau and improves repeated mild traumatic brain injury outcomes.

  2016cites this paper
• The role of neurogenesis during development and in the adult brain

  2016cites this paper
• Gene Therapy Models of Alzheimer's Disease and Other Dementias.

  2016cites this paper
• Neurogenesis-based epigenetic therapeutics for Alzheimer's disease (Review).

  2016cites this paper
• Sodium selenate retards epileptogenesis in acquired epilepsy models reversing changes in protein phosphatase 2A and hyperphosphorylated tau.

  2016cites this paper
• Effect of CNTF Derived Peptide, P021 on Cognition and Pathology in 3xTG-AD Mouse Model of Alzheimer's Disease

  2016influential citation
• Zinc Finger and X-Linked Factor (ZFX) Binds to Human SET Transcript 2 Promoter and Transactivates SET Expression

  2016cites this paper
• Increases of SET level and translocation are correlated with tau hyperphosphorylation at ser202/thr205 in CA1 of Ts65Dn mice.

  2016cites this paper
• 7,8-Dihydroxyflavone as a pro-neurotrophic treatment for neurodevelopmental disorders.

  2015cites this paper
• Sera from Children with Autism Induce Autistic Features Which Can Be Rescued with a CNTF Small Peptide Mimetic in Rats

  2015cites this paper
• Sodium selenate reduces hyperphosphorylated tau and improves outcomes after traumatic brain injury.

  2015influential citation
• Intracerebroventricular oxytocin administration in rats enhances object recognition and increases expression of neurotrophins, microtubule‐associated protein 2, and synapsin I

  2015cites this paper
• Inhibition of Protein Phosphatase-2A (PP2A) by I1PP2A Leads to Hyperphosphorylation of Tau, Neurodegeneration, and Cognitive Impairment in Rats

  2015cites this paper
• The impact of ginsenosides on cognitive deficits in experimental animal studies of Alzheimer’s disease: a systematic review

  2015cites this paper
• Memantine Attenuates Alzheimer’s Disease-Like Pathology and Cognitive Impairment

  2015cites this paper
• Microtubule-associated protein tau as a therapeutic target in Alzheimer's disease

  2014cites this paper
• Upregulation of SET Expression by BACE1 and its Implications in Down Syndrome

  2014cites this paper
• The Role of Cholesterol Metabolism in Alzheimer’s Disease

  2014cites this paper
• Abnormal ) PP 2 A 2 Phosphatase 2 A Inhibitor 2 ( I Cytoplasmic Retention of Protein Neurobiology :

  2014cites this paper
• The Potential Role of Rho GTPases in Alzheimer's Disease Pathogenesis

  2014cites this paper
• Alzheimer disease therapeutics: focus on the disease and not just plaques and tangles.

  2014cites this paper
• Therapeutic benefits of a component of coffee in a rat model of Alzheimer's disease.

  2014influential citation
• SET translocation is associated with increase in caspase cleaved amyloid precursor protein in CA1 of Alzheimer and Down syndrome patients.

  2014cites this paper
• Neurogenesis in neurological and psychiatric diseases and brain injury: from bench to bedside.

  2014cites this paper
• Neonatal manipulation of oxytocin prevents lipopolysaccharide-induced decrease in gene expression of growth factors in two developmental stages of the female rat.

  2014cites this paper
• Cytoplasmic Retention of Protein Phosphatase 2A Inhibitor 2 (I2PP2A) Induces Alzheimer-like Abnormal Hyperphosphorylation of Tau*

  2014cites this paper
• Shifting balance from neurodegeneration to regeneration of the brain: a novel therapeutic approach to Alzheimer's disease and related neurodegenerative conditions

  2014cites this paper
• Cytoplasmic SET induces tau hyperphosphorylation through a decrease of methylated phosphatase 2A

  2014cites this paper
• Disease modifying effect of chronic oral treatment with a neurotrophic peptidergic compound in a triple transgenic mouse model of Alzheimer's disease.

  2014cites this paper
• The Therapeutic Potential of Atorvastatin in a Mouse Model of Postoperative Cognitive Decline

  2014cites this paper
• Rescue of cognitive-aging by administration of a neurogenic and/or neurotrophic compound.

  2014cites this paper
• Activation of Asparaginyl Endopeptidase Leads to Tau Hyperphosphorylation in Alzheimer Disease*

  2013cites this paper
• Ser9 phosphorylation causes cytoplasmic detention of I2PP2A/SET in Alzheimer disease.

  2013cites this paper
• Hyperphosphorylation-Induced Tau Oligomers

  2013cites this paper
• Can We Teach Old Dogs New Tricks? Neuroprotective Cell Therapy in Alzheimer's and Parkinson's Disease

  2013cites this paper
• Molecular changes during the development of Alzheimer's disease Summary and general discussion 6 increased oxidative stress and free radical formation, DNA damage, disturbed energy metabolism and synaptic and neuronal degeneration.

  2013cites this paper
• Neurogenic and Neurotrophic Effects of BDNF Peptides in Mouse Hippocampal Primary Neuronal Cell Cultures

  2013cites this paper
• A truncated peptide from p35, a Cdk5 activator, prevents Alzheimer's disease phenotypes in model mice

  2013cites this paper
• Animal Models of the Sporadic Form of Alzheimer's Disease: Focus on the Disease and Not Just the Lesions

  2013cites this paper
• Glycogen synthase kinase 3 inhibition promotes adult hippocampal neurogenesis in vitro and in vivo.

  2012cites this paper
• Abnormal Hyperphosphorylation of Tau: Sites, Regulation, and Molecular Mechanism of Neurofibrillary Degeneration

  2012cites this paper
• delta-secretase in neurodegenerative diseases: mechanisms, regulators and therapeutic opportunities

  year unknowncites this paper